Resolution criteria

This market will resolve to YES if Bryan Johnson publicly confirms or provides verifiable evidence that he has personally ingested, taken, or participated in a clinical trial involving the experimental drug RTR242 at any time on or before December 31, 2033. The market will resolve to NO if, by that date, no such confirmation or evidence exists.

Acceptable evidence includes, but is not limited to:

• Official statements or documentation from Bryan Johnson’s social media channels, website (bryanjohnson.com), or Project Blueprint publications.

• Credible third-party reporting or documentation of clinical trial participation involving Johnson and RTR242.

Background

RTR242 is an experimental drug candidate developed by Retro Biosciences, a longevity-focused biotech company backed by investors including Sam Altman. The drug is designed to boost autophagy—a cellular recycling process—with the goal of targeting age-related conditions such as Alzheimer's and Parkinson's disease. As of early 2026, Retro Biosciences has reportedly initiated clinical trials for RTR242. Bryan Johnson is a prominent figure in the longevity space, known for his "Project Blueprint" regimen, which involves intensive, data-driven health interventions and frequent self-experimentation.

This description was generated by AI. Review and verify everything here yourself. You can edit, replace, or delete any part of this description, including the resolution criteria. You do not need to trust the AI output.